ANTI-INFLAMMATORY AND ANTI-ANGIOGENIC POTENTIAL OF CROMOLYN IN 7, 12-DIMETHYLBENZ(A)ANTHRACENE INDUCED HAMSTER BUCCAL POUCH CARCINOGENESIS
Objectives: Cromolyn, a potent and safe anti-inflammatory drug, is used as a safe medication for the prophylactic treatment of asthma. The present study explores its anti-inflammatory and anti-angiogenic potential of cromolyn by analysing the expression pattern of inflammatory (NF-ÎºB, COX-2, iNOS, IL-6 and IL-10) and angiogenic (VEGF) in 7, 12-dimethylbenz (a) anthracene (DMBA) induced hamster buccal pouch carcinogenesis.
Methods: Topical application of 0.5% DMBA (three times a week) in the buccal pouches of hamsters resulted in well differentiated squamous cell carcinoma after 14 w*.
Results: While tumor formation was observed in all the hamsters treated with DMBA alone, we noticed only precancerous lesions such as hyperkeratosis, hyperplasia, and mild dysplasia in DMBA+cromolyn treated hamsters. Furthermore, cromolyn prevented the dysregulation induced by DMBA on the expression pattern of inflammatory and angiogenic markers.
Conclusion: The present study thus concludes that the tumor preventive potential of cromolyn relies on its anti-inflammatory and anti-angiogenic potential in 7, 12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis.
2. Sridharan G. Epidemiology, control and prevention of tobacco induced oral mucosal lesion in India. Indian J Cancer 2014;51:80-5.
3. Manoharan S, Wani SA, Vasudevan K, Manimaran A, Prabhakar MM. Saffron reduction of 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. Asian Pacific J Cancer Prevention 2013;14:951-7.
4. Manoharan S, Panjamurthy K, Pugalendi P, Balakrishnan S, Rajalingam K, Vellaichamy L, et al. Protective role of Withaferin-A on red blood cell integrity during 7,12-dimethylbenz[a]anthracene induced oral carcinogenesis. Afr J Tradit Complementary Altern Med 2008;6:94-102.
5. Wei J, Xie G, Ge S, Qiu Y, Liu W, Lu A, et al. Metabolic transformation of DMBA-induced carcinogenesis and the inhibitory effect of salvianolic acid b and brovincamine treatment. J Proteome Res 2012;11:1302-16.
6. Radley HG, Grounds MD. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol Dis 2006;23:387-97.
7. Motawi TM, Bustanji Y, EL-Maraghy SA, Taha MO, AlGhussein MAS. Naproxen and Cromolyn as new glycogen synthase kinase 3Î² Inhibitors for the amelioration of diabetes and obesity: An investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol 2013;27:425-36.
8. Ionov ID. Inhibition of mast cell activity as a new approach to anticancer therapy. Int J Radiat Biol 1991;60;287-91.
9. Motawi TM, Bustanji Y, El-Maraghy S, Taha MO, Al-Ghussein MA. Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, P53 and gene expression of survivin and caspase-3. J Enzyme Inhib Med Chem 2014;29:153-61.
10. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806-18.
11. Beck PL, Morris GP, Wallace JL. Reduction of ethanol-induced gastric damage by sodium cromoglycate and FPL-52694. Role of beukotrienes, prostaglandins, and mast cells in the protective mechanism. Can J Physiol Pharmacol 1989;67:287-93.
12. Leone-Bay A, Leipold H, Sarubbi D, Variano B, Rivera T, Baughman RA. Oral delivery of sodium cromolyn: preliminary studies in vivo and in-vitro. Br J Pharm Res 1996;13:222-6.
13. Prabhakar MM, Vasudevan K, Karthikeyan S, Baskaran N, Silvan S, Manoharan S. Anti-cell proliferative efficacy of ferulic acid against 7,12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis. Asian Pacific J Cancer Prevention 2012;13:5207-11.
14. Nalini N, Aranganathan S, Kabalimurthy J. Chemopreventive efficacy of hesperetin (citrus flavanone) against 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Toxicol Mech Methods 2012;22:397-408.
15. Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: of all cancer cells, all the time?. Trends Mol Med 2012;18:509-15.
16. Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB (NF-kB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2007;43:395-401.
17. Shen HM, Tergaonkar V. NF-kB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009;14:34-8.
18. Johnson J, Shi Z, Liu Y, Stack MS. Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma. Oral Oncol 2014;50:468-77.
19. Bindhu OS, Ramadas K, Sebastian P, Pillai MR. High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head Neck Oncol 2006;28:916-25.
20. Zhang Z, Ma J, Li N, Sun N, Wang C. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Annals Thoracic Surgery 2006;82:243-8.
21. Pontes HA, Pontes FS, Fonseca FP, de Carvalho PL, Pereira EM, de Abreu MC, et al. Nuclear factor ÎºB and cyclooxygenase-2 immunoexpression in oral dysplasia and oral squamous cell carcinoma. Ann Diagn Pathol 2013;17:45-50.
22. Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, et al. Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer 2007;120:2545-56.
23. Wang LJ, Zhou X, Wang W, Tang F, Qi CL, Yang X, et al. Andrographolide inhibits oral squamous cell carcinogenesis through NF-ÎºB inactivation. J Dent Res 2011;90:1246-52.
24. Nagatsuka H, Siar CH, Tsujigiwa H, Naomoto Y, Han PP, Gunduz M, et al. Heparanase and cyclooxygenase-2 gene and protein expressions during the progression of oral epithelial dysplasia to carcinoma. Ann Diagn Pathol 2012;16:354-61.
25. Qian Y, Shao YS, Cao ZY. The role of COX-2 in tongue squamous cell carcinoma Tca8113 cell proliferation. Oral Med Res 2012;28:395-7.
26. Zhao M, Liu Y, Fu XL. The expression of COX-2 in oral papilloma, oral lichen planus and oral squamous cell carcinoma. Oral Med Res 2013;29:142-4.
27. Amirchaghmaghi M, Mohtasham N, Mozaffari PM. Comparison of COX2 expression between oral squamous cell carcinoma, leukoplakia and normal mucosa. J Contemporary Dental Practice 2012;13:205-9.
28. Wang ZM, Liu J, Liu HB, Ye M, Zhang YF, Yang DS. Abnormal COX2 protein expression may be correlated with poor prognosis in oral cancer: a meta-analysis. BioMed Res Int 2014;2014:364-7.
29. Seyedmajidi M, Shafaee S, Siadati S, Khorasani M, Bijani A, Ghasemi N. Cyclo-oxygenase-2 expression in oral squamous cell carcinoma. J Cancer Res Ther 2014;10:1024-9.
30. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.
31. Youn J, Lee JS, Na HK, Kundu JK, Surh YJ. Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. Nutr Cancer 2009;61:847-54.
32. Yang L, Wang Y, Guo L, Wang L, Chen W, Shi B. The expression and correlation of iNOS and p53 in oral squamous cell carcinoma. BioMed Res Int 2015;12. doi.org/ 10.1155/ 2015/637853. [Article in Press]
33. Crowell JA, Steele VE, Sigman CC, Fay JR. Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2003;2:815-23.
34. Brennan PA, Dennis S, Poller D, Quintero M, Puxeddu R, Thomas GJ. Inducible nitric oxide synthase: correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma. Head Neck Oncol 2008;30:208-14.
35. Tsai ML, Lai CS, Chang YH, Chen WJ, Ho CT, Pan MH. Pterostilbene, a natural analogue of resveratrol, potently inhibits 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin carcinogenesis. Food Funct 2012;3:1185-94.
36. Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M, et al. Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett 2007;253:34-42.
37. Tsai RL, Ho BY, Pan TM. Red mold rice mitigates oral carcinogenesis in 7,12-dimethyl-1,2-benz[a]anthracene-induced oral carcinogenesis in the hamster. J Evidence-Based Complementary Altern Med 2011:245-309. doi: 10.1093/ ecam/nep215. [Epub 2011 May 4]
38. Kishimoto K, Yoshida S, Ibaragi S, Yoshioka N, Okui T, Hu GF, et al. Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to the progression of oral cancer. Oral Oncol 2012;48:1120-7.
39. Aggarwal S, Devaraja K, Sharma SC, Das SN. Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance. Clin Chim Acta 2014;436:35-40.
40. Shang ZJ, Li JR, Li ZB. Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma. J Oral Maxillofac Surg 2007;65:17-21.
41. Lin HY, Hou SC, Chen SC, Kao MC, Yu CC, Funayama S, et al. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells. J Agric Food Chem 2012;60:2480-9.
42. Chuang JY, Huang YL, Yen WL, Chiang IP, Tsai MH, Tang CH. Syk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinoma. Int J Mol Sci 2014;15:545-59.
43. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling information and progression of malignant ascites in ovarian cancer. Cancer Res 2011;71:424-34.
44. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, et al. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 2003;106:683-9.
45. John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:929-35.
46. Chuang CY, Sung WW, Wang L, Lin WL, Yeh KT, Su MC, et al. Differential impact of IL-10 expression on survival and relapse between HPV16-positive and negative oral squamous cell carcinomas. PLoS One 2012;7:e47541.
47. Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, et al. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 2013;19:4092-103.
48. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukocyte Biol 2005;78:1043â€“51.
49. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res 2006;66:1491â€“9.
50. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996;2:1969-79.
51. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Nunez G, et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012;72:420-9.